Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD)
dc.contributor.author | Bilik, Dori | en_US |
dc.contributor.author | McEwen, Laura N. | en_US |
dc.contributor.author | Brown, Morton B. | en_US |
dc.contributor.author | Selby, Joe V. | en_US |
dc.contributor.author | Karter, Andrew J. | en_US |
dc.contributor.author | Marrero, David G. | en_US |
dc.contributor.author | Hsiao, Victoria C. | en_US |
dc.contributor.author | Tseng, Chien-Wen | en_US |
dc.contributor.author | Mangione, Carol M. | en_US |
dc.contributor.author | Lasser, Norman L. | en_US |
dc.contributor.author | Crosson, Jesse C. | en_US |
dc.contributor.author | Herman, William H. | en_US |
dc.date.accessioned | 2010-08-02T17:48:41Z | |
dc.date.available | 2011-03-01T16:26:42Z | en_US |
dc.date.issued | 2010-07 | en_US |
dc.identifier.citation | Bilik, Dori; McEwen, Laura N.; Brown, Morton B.; Selby, Joe V.; Karter, Andrew J.; Marrero, David G.; Hsiao, Victoria C.; Tseng, Chien-Wen; Mangione, Carol M.; Lasser, Norman L.; Crosson, Jesse C.; Herman, William H. (2010). "Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD)." Pharmacoepidemiology and Drug Safety 19(7): 715-721. <http://hdl.handle.net/2027.42/77529> | en_US |
dc.identifier.issn | 1053-8569 | en_US |
dc.identifier.issn | 1099-1557 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/77529 | |
dc.description.abstract | Background Studies have associated thiazolidinedione (TZD) treatment with cardiovascular disease (CVD) and questioned whether the two available TZDs, rosiglitazone and pioglitazone, have different CVD risks. We compared CVD incidence, cardiovascular (CV), and all-cause mortality in type 2 diabetic patients treated with rosiglitazone or pioglitazone as their only TZD. Methods We analyzed survey, medical record, administrative, and National Death Index (NDI) data from 1999 through 2003 from Translating Research Into Action for Diabetes (TRIAD), a prospective observational study of diabetes care in managed care. Medications, CV procedures, and CVD were determined from health plan (HP) administrative data, and mortality was from NDI. Adjusted hazard rates (AHR) were derived from Cox proportional hazard models adjusted for age, sex, race/ethnicity, income, history of diabetic nephropathy, history of CVD, insulin use, and HP. Results Across TRIAD's 10 HPs, 1,815 patients (24%) filled prescriptions for a TZD, 773 (10%) for only rosiglitazone, 711 (10%) for only pioglitazone, and 331 (4%) for multiple TZDs. In the seven HPs using both TZDs, 1,159 patients (33%) filled a prescription for a TZD, 564 (16%) for only rosiglitazone, 334 (10%) for only pioglitazone, and 261 (7%) for multiple TZDs. For all CV events, CV, and all-cause mortality, we found no significant difference between rosiglitazone and pioglitazone. Conclusions In this relatively small, prospective, observational study, we found no statistically significant differences in CV outcomes for rosiglitazone- compared to pioglitazone-treated patients. There does not appear to be a pattern of clinically meaningful differences in CV outcomes for rosiglitazone- versus pioglitazone-treated patients. Copyright © 2010 John Wiley & Sons, Ltd. | en_US |
dc.format.extent | 110366 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | John Wiley & Sons, Ltd. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Epidemiology, Biostatistics and Public Health | en_US |
dc.title | Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD) | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA ; Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA ; Professor of Internal Medicine and Epidemiology. ; Department of Epidemiology, 3920 Taubman Center, SPC 5354 Ann Arbor, MI 48109, USA. | en_US |
dc.contributor.affiliationother | Division of Research, Kaiser Permanente, Oakland, CA, USA | en_US |
dc.contributor.affiliationother | Division of Research, Kaiser Permanente, Oakland, CA, USA | en_US |
dc.contributor.affiliationother | Indiana University School of Medicine, Indianapolis, IN, USA | en_US |
dc.contributor.affiliationother | Pacific Health Research Institute and Department of Family Medicine and Community Health, University of Hawaii, Honolulu, HI, USA | en_US |
dc.contributor.affiliationother | Department of Medicine, University of California, Los Angeles, CA, USA | en_US |
dc.contributor.affiliationother | Preventive Cardiology Program, UMDNJ-New Jersey Medical School, Newark, NJ, USA | en_US |
dc.contributor.affiliationother | Department of Family Medicine, UMDNJ-Robert Wood Johnson Medical School, Somerset, NJ, USA | en_US |
dc.identifier.pmid | 20583206 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/77529/1/1954_ftp.pdf | |
dc.identifier.doi | 10.1002/pds.1954 | en_US |
dc.identifier.source | Pharmacoepidemiology and Drug Safety | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.